Guiyang Xintian Pharmaceutical Co.,Ltd.

Equities

002873

CNE100002QB5

Pharmaceuticals

End-of-day quote Shenzhen S.E. 06:00:00 2024-05-16 pm EDT 5-day change 1st Jan Change
11.39 CNY -1.73% Intraday chart for Guiyang Xintian Pharmaceutical Co.,Ltd. -5.24% -8.59%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Guiyang Xintian Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Guiyang Xintian Pharmaceutical Co.,Ltd. Announces Profit Distribution Proposal for 2023 CI
Guiyang Xintian Pharmaceutical Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Guiyang Xintian Pharmaceutical Co.,Ltd. signed Transaction Framework Agreement to acquire remaining 85.12% stake in Shanghai Huilun Biotechnology Co., Ltd. CI
Tranche Update on Guiyang Xintian Pharmaceutical Co.,Ltd.'s Equity Buyback Plan announced on February 6, 2024. CI
Guiyang Xintian Pharmaceutical Co.,Ltd. announces an Increase in Equity Buyback. CI
Guiyang Xintian Pharmaceutical Co.,Ltd. announces an Equity Buyback for CNY 50 million worth of its shares. CI
Guiyang Xintian Pharmaceutical Co.,Ltd. authorizes a Buyback Plan. CI
Tranche Update on Guiyang Xintian Pharmaceutical Co.,Ltd.'s Equity Buyback Plan announced on December 23, 2023. CI
Guiyang Xintian Pharmaceutical Co.,Ltd.'s Equity Buyback announced on December 23, 2023 has closed with 4,017,200 shares, representing 1.73% for CNY 38.41 million. CI
Guiyang Xintian Pharmaceutical Co.,Ltd. announces an Increase in Equity Buyback. CI
Tranche Update on Guiyang Xintian Pharmaceutical Co.,Ltd.'s Equity Buyback Plan announced on December 23, 2023. CI
Guiyang Xintian Pharmaceutical Co.,Ltd. announces an Equity Buyback for CNY 15 million worth of its shares. CI
Guiyang Xintian Pharmaceutical Co.,Ltd. authorizes a Buyback Plan. CI
Guiyang Xintian Pharmaceutical Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Guiyang Xintian Pharmaceutical Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Guiyang Xintian Pharmaceutical Co.,Ltd. Announces Cash Dividend on A Shares for the Year 2022, Payable on 01 June 2023 CI
Guiyang Xintian Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Guiyang Xintian Pharmaceutical Co.,Ltd. Approves Cash Dividend for the Year of 2022 CI
Guiyang Xintian Pharmaceutical Co.,Ltd. Proposes Final Cash Dividend for the Year of 2022 CI
Guiyang Xintian Pharma Tapped to Produce Traditional Chinese Medicine for Hospital MT
Shanghai Huilun Biotechnology Co., Ltd. announced that it has received CNY 102 million in funding from Guiyang Xintian Pharmaceutical Co.,Ltd. and other investors CI
Shanghai Huilun Biotechnology Co., Ltd. announced that it expects to receive CNY 102 million in funding from Guiyang Xintian Pharmaceutical Co.,Ltd. and other investors CI
Guiyang Xintian Pharmaceutical Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022 CI
Guiyang Xintian Pharmaceutical Co.,Ltd. Announces 2021 Final Profit Distribution Plan, Payable on 7 July 2022 CI
Chart Guiyang Xintian Pharmaceutical Co.,Ltd.
More charts
Guiyang Xintian Pharmaceutical Co., Ltd. is a China-based company principally engaged in the research, development, production and sales of Chinese patent drugs. The Company manufactures its products in the forms of capsules, mixture, granules, syrup, gel and tablets. The Company’s main products include Ningmitai Capsule, Kuntai Capsule, Kushen Gel and Xiaokucao Oral Liquid .The Company distributes its products in the domestic market.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
11.39
Average target price
-
Consensus

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. 002873 Stock
  4. News Guiyang Xintian Pharmaceutical Co.,Ltd.
  5. Guiyang Xintian Pharma Tapped to Produce Traditional Chinese Medicine for Hospital
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW